Stanozolol promotes osteogenic gene expression and apposition of bone mineral in vitro
AUTOR(ES)
Ghiacci, Giulia, Lumetti, Simone, Manfredi, Edoardo, Mori, Daniele, Macaluso, Guido Maria, Sala, Roberto
FONTE
J. Appl. Oral Sci.
DATA DE PUBLICAÇÃO
08/11/2018
RESUMO
Abstract Stanozolol (ST) is a synthetic androgen with high anabolic potential. Although it is known that androgens play a positive role in bone metabolism, ST action on bone cells has not been sufficiently tested to support its clinical use for bone augmentation procedures. Objective: This study aimed to assess the effects of ST on osteogenic activity and gene expression in SaOS-2 cells. Material and Methods: SaOS-2 deposition of mineralizing matrix in response to increasing doses of ST (0-1000 nM) was evaluated through Alizarin Red S and Calcein Green staining techniques at 6, 12 and 24 days. Gene expression of runt-related transcription factor 2 (RUNX2), vitamin D receptor (VDR), osteopontin (SPP1) and osteonectin (ON) was analyzed by RT-PCR. Results: ST significantly influenced SaOS-2 osteogenic activity: stainings showed the presence of rounded calcified nodules, which increased both in number and in size over time and depending on ST dose. RT-PCR highlighted ST modulation of genes related to osteogenic differentiation. Conclusions: This study provided encouraging results, showing ST promoted the osteogenic commitment of SaOS-2 cells. Further studies are required to validate these data in primary osteoblasts and to investigate ST molecular pathway of action.
Documentos Relacionados
- Stimulation of the expression of osteogenic and chondrogenic phenotypes in vitro by osteogenin.
- Enhanced bone apposition to Brazilian microrough titanium surfaces
- Bone mineral density and bone turnover in spinal osteoarthrosis.
- Bone mineral density and bone turnover in spinal osteoarthritis.
- 5-Azacytidine facilitates osteogenic gene expression and differentiation of mesenchymal stem cells by alteration in DNA methylation